(Q53380746)

13 May 2018

title

CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies. (English)

1 reference

13 May 2018

0 references

0 references

8

1 reference

13 May 2018

Jens Wiltfang

10

1 reference

13 May 2018

Piotr Lewczuk

4

object named as

P Lewczuk

1 reference

13 May 2018

author name string

M Bibl

1

1 reference

13 May 2018

B Mollenhauer

2

1 reference

13 May 2018

H Esselmann

3

1 reference

13 May 2018

C Trenkwalder

5

1 reference

13 May 2018

P Brechlin

6

1 reference

13 May 2018

E Rüther

7

1 reference

13 May 2018

M Otto

9

1 reference

13 May 2018

publication date

17 August 2006

1 reference

13 May 2018

Journal of Neural Transmission

published in

1 reference

13 May 2018

volume

113

1 reference

13 May 2018

issue

11

1 reference

13 May 2018

page(s)

1771-1778

1 reference

13 May 2018

https://scigraph.springernature.com/pub.10.1007/s00702-006-0537-z

exact match

0 references

cites work

Reliability and Validity of NINCDS-ADRDA Criteria for Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1007%2FS00702-006-0537-Z

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-006-0537-Z

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-006-0537-Z

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-006-0537-Z

Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-006-0537-Z

Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-006-0537-Z

Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide

21 January 2018

1 reference

12 December 2020

Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy

1 reference

12 December 2020

Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.

1 reference

12 December 2020

Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities

1 reference

12 December 2020

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

1 reference

12 December 2020

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice

1 reference

12 December 2020

Plaque-only Alzheimer disease is usually the lewy body variant, and vice versa.

1 reference

12 December 2020

Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies

1 reference

12 December 2020

Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

1 reference

12 December 2020

Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases

1 reference

12 December 2020

Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture

1 reference

12 December 2020

1 reference

12 December 2020

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

12 December 2020

Study of the conformational transition of A beta(1-42) using D-amino acid replacement analogues

1 reference

12 December 2020

A68: a major subunit of paired helical filaments and derivatized forms of normal Tau.

1 reference

12 December 2020

CSF markers for Alzheimer's disease: Total tau, phospho-tau and Aβ42

1 reference

12 December 2020

Amyloid beta-peptide and its relationship with dementia in Lewy body disease.

1 reference

12 December 2020

Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.

1 reference

12 December 2020

Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau.

1 reference

12 December 2020

Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells.

1 reference

12 December 2020

Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies

1 reference

12 December 2020

Cerebrospinal fluid amyloidβ peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidβ peptides

1 reference

12 December 2020

Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias.

1 reference

12 December 2020

Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia.

1 reference

12 December 2020

10.1007/S00702-006-0537-Z

Identifiers

DOI

1 reference

13 May 2018

PubMed ID

16906356

1 reference

13 May 2018